Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 284,707 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the completion of the sale, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Trading Up 3.1%

NASDAQ ROIV opened at $37.37 on Wednesday. Roivant Sciences Ltd. has a 1-year low of $11.54 and a 1-year high of $37.46. The firm’s fifty day simple moving average is $34.16 and its 200-day simple moving average is $30.17. The company has a market capitalization of $26.99 billion, a PE ratio of -70.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. As a group, analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Institutional Trading of Roivant Sciences

Several large investors have recently made changes to their positions in ROIV. Morgan Stanley raised its stake in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Vanguard Group Inc. boosted its position in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after purchasing an additional 3,254,113 shares during the period. Rubric Capital Management LP grew its holdings in Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. State Street Corp grew its holdings in Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after purchasing an additional 911,827 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Guggenheim increased their price target on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.